ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Michael Kuhrt contributed 541 entries already.
The past two years could be called the years of messenger RNA (mRNA) technology, with two major biotech companies, BioNTech and Moderna, playing a crucial role in the development of vaccines against COVID-19 and showing the world the way out of the pandemic, along with achieving record sales revenues.
The COVID-19 pandemic has demonstrated how vulnerable human beings and societies are to a new infectious disease, and how important the life science industry is to come up with diagnostic and therapeutic solutions.
At the beginning of September, Stephan Goldenbaum became the new CEO of Estonian Solis BioDyne OÜ. CEO Priit Karjus stepped down to continue the Supervisory Board.
Timo van den Berg is the new senior director Immuno-Oncology Research and Development at Byondis B.V. He joined the company at beginning
Dr Neil Butt is the new Chief Executive Officer at Oxford-based Orbit Discovery.
Malene Brondberg, Chief Financial Officer of Nordic Nanovector since May 2020, became Interim Chief Executive Officer of the company.
Dr Stefano Portolano, M.D., is the new Chief Executive Officer of Azafaros and has been appointed to the Board of Directors of the Dutch company.
At the beginning of June, Sidonie Fabre strengthens Advent France Biotechnology (AFB) as new Chief Financial Officer.
New entrants and variants will be main drivers of the COVID-19 vaccine market as supply gradually begins
to catch up with demand.
Tom Graney, until now CFO of Belgian Oxurion nv, took over from CEO Patrik De Haes. De Haes becomes Non-executive Chairman of the Biopharmaceutical company, spezialised in retinal disorders.